Nektar Therapeutics (NASDAQ:NKTR) Stock Has Average Price Target of $130.67 According to Brokerages

Shares of Nektar Therapeutics (NASDAQ:NKTR) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $130.67.

A number of brokerages have weighed in on NKTR. Leerink Partners assumed coverage on shares of Nektar Therapeutics in a report on Monday, October 12th. They issued an “outperform” rating and a $130.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $185.00 target price on shares of Nektar Therapeutics in a report on Friday, October 2nd. TD Cowen upgraded shares of Nektar Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reissued a “buy” rating and issued a $178.00 price target on shares of Nektar Therapeutics in a research report on Friday, October 9th. Finally, JPMorgan Chase & Co. initiated coverage on Nektar Therapeutics in a research note on Friday, August 21st. They issued a “neutral” rating and a $65.00 price target on the stock.

Nektar Therapeutics Price Performance

NASDAQ:NKTR opened at $38.87 on Monday. The firm’s 50-day moving average price is $55.69 and its 200-day moving average price is $64.50. The company has a market capitalization of $1.33 billion, a PE ratio of -5.80 and a beta of 1.45. Nektar Therapeutics has a 1-year low of $33.40 and a 1-year high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.97) by $0.74. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. The company had revenue of $10.13 million during the quarter, compared to analyst estimates of $10.43 million. Equities analysts anticipate that Nektar Therapeutics will post -8.08 EPS for the current fiscal year.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of Nektar Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer owned 54,627 shares in the company, valued at approximately $3,932,051.46. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Two Seas Capital LP raised its position in shares of Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock worth $202,582,000 after purchasing an additional 253,744 shares during the last quarter. Braidwell LP grew its position in Nektar Therapeutics by 112.7% during the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after purchasing an additional 250,916 shares during the last quarter. Emerald Advisers LLC grew its position in Nektar Therapeutics by 2.7% during the 1st quarter. Emerald Advisers LLC now owns 394,604 shares of the biopharmaceutical company’s stock valued at $28,392,000 after purchasing an additional 10,262 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Nektar Therapeutics during the 1st quarter valued at about $19,786,000. Finally, Emerald Mutual Fund Advisers Trust increased its stake in Nektar Therapeutics by 1.2% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 256,106 shares of the biopharmaceutical company’s stock valued at $18,427,000 after purchasing an additional 2,981 shares in the last quarter. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for autoimmune, inflammatory and other serious diseases. The company uses its proprietary biologics and polymer-conjugation technologies to design therapies intended to improve immune-system regulation, drug activity and dosing convenience.

Nektar’s pipeline includes rezpegaldesleukin, an investigational treatment designed to expand regulatory T cells and potentially restore immune tolerance in conditions such as atopic dermatitis, alopecia areata and other autoimmune diseases.